1 / 1

TIMACS

TIMACS. No difference in primary outcome between the two arms (HR 0.85, 95% CI 0.68-1.06), except in high-risk patients (HR 0.65, 95% CI 0.48-0.89, p = 0.006)

quamar-slater
Download Presentation

TIMACS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TIMACS No difference in primary outcome between the two arms (HR 0.85, 95% CI 0.68-1.06), except in high-risk patients (HR 0.65, 95% CI 0.48-0.89, p = 0.006) Death, MI, refractory ischemia ↓ in early invasive arm (p = 0.003), due to ↓ in refractory ischemia (p < 0.001); death (p = 0.19), stroke (p = 0.74) similar Major bleeding was similar (p = 0.55) (p = 0.15) (p = 0.19) Delayed invasive (n = 1,438) Early invasive (n = 1,593) Trial design: Patients with NSTEMI were randomized to an early (within 24 hours) or delayed (after 36 hours) invasive strategy. Clinical outcomes were compared at 6 months. Results 20 20 15 15 11.3 % % 9.6 10 10 5.9 Conclusions 4.8 5 5 • Early invasive strategy is not associated with harm compared with delayed invasive strategy in patients with NSTEMI, and may be beneficial in high-risk patients • Significant reduction in refractory ischemia with an early invasive strategy 0 0 Primary endpoint Mortality Mehta SR, et al. N Engl J Med 2009;360:2165-75

More Related